Anna Erickson

Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment

Over the past decade there has been a growth in the development of pathogen reduction technologies to protect the blood supply from emerging pathogens. This development has proven to be difficult for red blood cells (RBCs). However the S‐303 system has been shown to effectively inactivate a broad spectrum of pathogens, while maintaining RBC quality.

Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study

Pathogen reduction technology using amustaline (S‐303) was developed to reduce the risk of transfusion‐transmitted infection and adverse effects of residual leucocytes. In this study, the viability of red blood cells (RBCs) prepared with a second‐generation process and stored for 35 days was evaluated in two different blood centres.

Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery: AMUSTALINE RBCs IN CARDIAC SURGERY

Nucleic acid–targeted pathogen inactivation technology using amustaline (S‐303) and glutathione (GSH) was developed to reduce the risk of transfusion‐transmitted infectious disease and transfusion‐associated graft‐versus‐host disease with red blood cell (RBC) transfusion.